Utah Medical Products, Inc. has released its second quarter 2025 financial results, reporting a 4.3% decline in revenue compared to the same period in 2024, with figures standing at $9.953 million from $10.4 million. The company experienced a contraction in its gross profit margin primarily due to lower than expected sales and an unfavorable product mix, particularly in its Ireland operations. Despite these challenges, operating income declined less than the gross profit due to reduced U.S. litigation costs. Net operating income for the first half of 2025 was $1.345 million, compared to $1.688 million in the first half of 2024. The company attributed part of this decline to lower interest income resulting from reduced cash balances due to share repurchases and lower interest rates. However, foreign currency remeasurements contributed positively with a $7,000 increase in net operating income compared to the previous year. The company has maintained a strong balance sheet with no debt and ending cash and investments totaling $82.2 million as of June 30, 2025. This is a slight decrease from $83.0 million at the end of 2024, following cash dividends, stock repurchases, and capital expenditures during the first half of 2025. Looking forward, Utah Medical Products anticipates that sales to an OEM customer will be approximately $2 million lower for the year 2025 compared to 2024. This expectation aligns with the projections provided at the beginning of the year.